共有 50 笔近期内部人交易记录记录，涉及 Biogen Inc. (BIIB), 包括 23 笔买入 和 26 笔卖出. 内部人买入总额为 $152.14K 内部人卖出总额为 $2.46M.
近期活跃的重要内部人包括 Godbout Sean, Alexander Susan H, Gregory Ginger. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — BIIB
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2026-04-01 |
Godbout Sean |
Chief Accounting Officer |
期权行权（卖出） |
181 |
- |
- |
364 |
| 2026-02-13 |
Alexander Susan H |
EVP Chief Legal Officer |
限制性股票授予 (RSU) |
8,450 |
- |
- |
8,450 |
| 2026-02-13 |
Gregory Ginger |
EVP, Human Resources |
限制性股票授予 (RSU) |
8,025 |
- |
- |
8,025 |
| 2026-02-13 |
Kramer Robin |
Chief Financial Officer |
限制性股票授予 (RSU) |
8,450 |
- |
- |
8,450 |
| 2026-02-13 |
Singhal Priya |
Head of Development |
限制性股票授予 (RSU) |
10,560 |
- |
- |
10,560 |
| 2026-02-13 |
Viehbacher Christopher |
President and CEO |
限制性股票授予 (RSU) |
38,015 |
- |
- |
38,015 |
| 2026-02-13 |
Izzar Rachid |
Head of Global Product Strat. |
限制性股票授予 (RSU) |
7,390 |
- |
- |
7,390 |
| 2026-02-13 |
Murphy Nicole |
Head of Pharm Ops and Tech |
限制性股票授予 (RSU) |
10,560 |
- |
- |
10,560 |
| 2026-02-13 |
Keeney Adam |
Head of Corporate Development |
限制性股票授予 (RSU) |
8,025 |
- |
- |
8,025 |
| 2026-02-13 |
Grogan Jane |
Head of Research |
限制性股票授予 (RSU) |
8,450 |
- |
- |
8,450 |
| 2026-02-13 |
Godbout Sean |
Chief Accounting Officer |
限制性股票授予 (RSU) |
1,800 |
- |
- |
1,800 |
| 2026-02-12 |
Murphy Nicole |
Head of Pharm Ops and Tech |
知情买入 |
3 |
$195.04 |
$585.11 |
19,611 |
| 2026-02-09 |
Singhal Priya |
Head of Development |
知情卖出 |
2,660 |
$199.83 |
$531.55K |
8,043 |
| 2026-02-06 |
Alexander Susan H |
EVP Chief Legal Officer |
期权行权（卖出） |
2,190 |
- |
- |
- |
| 2026-02-06 |
Gregory Ginger |
EVP, Human Resources |
期权行权（卖出） |
1,635 |
- |
- |
- |
| 2026-02-06 |
Kramer Robin |
Chief Financial Officer |
期权行权（卖出） |
789 |
- |
- |
- |
| 2026-02-06 |
Singhal Priya |
Head of Development |
期权行权（卖出） |
2,217 |
- |
- |
2,217 |
| 2026-02-06 |
Viehbacher Christopher |
President and CEO |
期权行权（卖出） |
9,008 |
- |
- |
9,009 |
| 2026-02-06 |
Izzar Rachid |
Head of Global Product Strat. |
期权行权（卖出） |
2,044 |
- |
- |
- |
| 2026-02-06 |
Murphy Nicole |
Head of Pharm Ops and Tech |
期权行权（卖出） |
2,102 |
- |
- |
- |
| 2026-02-06 |
Keeney Adam |
Head of Corporate Development |
期权行权（卖出） |
1,802 |
- |
- |
1,802 |
| 2026-02-06 |
Grogan Jane |
Head of Research |
期权行权（卖出） |
1,385 |
- |
- |
1,385 |
| 2026-02-06 |
Godbout Sean |
Chief Accounting Officer |
期权行权（卖出） |
257 |
- |
- |
- |
| 2026-02-02 |
Singhal Priya |
Head of Development |
知情卖出 |
748 |
$179.30 |
$134.12K |
6,271 |
| 2026-01-30 |
Singhal Priya |
Head of Development |
期权行权（卖出） |
1,829 |
- |
- |
- |
| 2025-12-01 |
Viehbacher Christopher |
President and CEO |
期权行权（卖出） |
7,040 |
- |
- |
- |
| 2025-06-17 |
Sherwin Stephen A |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
13,688 |
| 2025-06-17 |
Hawkins William A |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
8,860 |
| 2025-06-17 |
Dorsa Caroline |
Director |
限制性股票授予 (RSU) |
3,160 |
- |
- |
31,002 |
| 2025-06-17 |
Rowinsky Eric K |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
24,339 |
| 2025-06-17 |
Freire Maria C |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
6,815 |
| 2025-06-17 |
Mantas Jesus B |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
9,758 |
| 2025-06-17 |
Patolawala Monish D |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
3,710 |
| 2025-06-17 |
Langer Susan |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
5,129 |
| 2025-06-17 |
Pangalos Menelas N |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
2,370 |
| 2025-06-17 |
Minor Lloyd |
Director |
限制性股票授予 (RSU) |
2,370 |
- |
- |
2,370 |
| 2025-05-19 |
Singhal Priya |
Head of Development |
知情卖出 |
3,806 |
$126.25 |
$480.51K |
5,427 |
| 2025-05-02 |
Dorsa Caroline |
Director |
知情买入 |
1,235 |
$122.72 |
$151.56K |
27,842 |
| 2025-05-01 |
Keeney Adam |
Head of Corporate Development |
期权行权（卖出） |
938 |
- |
- |
939 |
| 2025-04-01 |
Godbout Sean |
Chief Accounting Officer |
限制性股票授予 (RSU) |
545 |
- |
- |
545 |
| 2025-03-07 |
Sherwin Stephen A |
Director |
知情卖出 |
8,760 |
$150.02 |
$1.31M |
11,318 |
| 2025-03-01 |
Godbout Sean |
Chief Accounting Officer |
未知 |
257 |
- |
- |
- |
| 2025-02-10 |
Mcdonnell Michael R |
EVP, Chief Financial Officer |
期权行权（卖出） |
3,257 |
- |
- |
- |
| 2025-02-10 |
Alexander Susan H |
EVP Chief Legal Officer |
期权行权（卖出） |
2,575 |
- |
- |
- |
| 2025-02-10 |
Gregory Ginger |
EVP, Human Resources |
期权行权（卖出） |
2,159 |
- |
- |
- |
| 2025-02-10 |
Kramer Robin |
Chief Accounting Officer |
期权行权（卖出） |
834 |
- |
- |
- |
| 2025-02-10 |
Singhal Priya |
Head of Development |
期权行权（卖出） |
1,212 |
- |
- |
- |
| 2025-02-10 |
Izzar Rachid |
Head of Global Product Strat. |
期权行权（卖出） |
1,515 |
- |
- |
- |
| 2025-02-10 |
Murphy Nicole |
Head of Pharm Ops and Tech |
期权行权（卖出） |
2,272 |
- |
- |
- |
| 2025-02-07 |
Mcdonnell Michael R |
EVP, Chief Financial Officer |
期权行权（卖出） |
2,335 |
- |
- |
2,335 |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
